Rezolute (NASDAQ:RZLT) CEO Purchases $50,880.00 in Stock

Key Points

• CEO Nevan Elam bought 32,000 shares at $1.59 on Dec. 15 for a total of $50,880, increasing his stake to 641,119 shares (a 5.25% rise) as disclosed in an SEC Form 4.
• Rezolute shares traded at $1.63 with heavy volume (13.38M vs. a 9.71M average), a market cap of $151.15M and a negative P/E of -1.75, with a 52-week range of $1.07–$11.46.
• The stock has a consensus analyst rating of "Hold" with a $9.78 target amid mixed downgrades and some buy calls, ~82.97% institutional ownership, and the company is a clinical-stage biopharma whose lead candidate RZ358 is in Phase 2b.

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) CEO Nevan Elam purchased 32,000 shares of the company's stock in a transaction that occurred on Monday, December 15th. The stock was acquired at an average cost of $1.59 per share, for a total transaction of $50,880.00. Following the transaction, the chief executive officer owned 641,119 shares in the company, valued at $1,019,379.21. This represents a 5.25% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Rezolute Stock Performance

RZLT traded down $0.17 during midday trading on Monday, reaching $1.63. 13,380,965 shares of the company were exchanged, compared to its average volume of 9,712,468. The company has a market cap of $151.15 million, a price-to-earnings ratio of -1.75 and a beta of 0.21. Rezolute, Inc. has a one year low of $1.07 and a one year high of $11.46. The company's fifty day moving average price is $9.00 and its 200 day moving average price is $7.17.

Rezolute (NASDAQ:RZLT - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.09. As a group, sell-side analysts anticipate that Rezolute, Inc. will post -0.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

RZLT has been the subject of several analyst reports. Cantor Fitzgerald downgraded shares of Rezolute from an "overweight" rating to a "neutral" rating in a report on Thursday. Wedbush cut shares of Rezolute from an "outperform" rating to a "neutral" rating in a research report on Thursday. BTIG Research reaffirmed a "buy" rating and issued a $5.00 target price on shares of Rezolute in a report on Thursday. Citizens Jmp lowered Rezolute from a "strong-buy" rating to a "hold" rating in a report on Thursday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Rezolute in a research note on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $9.78.

Institutional Investors Weigh In On Rezolute

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new position in shares of Rezolute in the second quarter valued at approximately $25,000. Ameritas Investment Partners Inc. bought a new position in shares of Rezolute in the second quarter worth approximately $30,000. Legal & General Group Plc bought a new stake in Rezolute during the second quarter valued at approximately $32,000. Raymond James Financial Inc. bought a new position in shares of Rezolute in the 2nd quarter worth $46,000. Finally, Paloma Partners Management Co bought a new position in shares of Rezolute in the 1st quarter worth $48,000. 82.97% of the stock is currently owned by institutional investors.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.